Glyceryl Behenate and Its Suitability for Production of Aceclofenac Solid Lipid Nanoparticles

被引:24
作者
Chawla, Viney [2 ]
Saraf, Shubhini A. [1 ]
机构
[1] Babu Banarasi Das Natl Inst Technol & Management, Fac Pharm, Lucknow 227105, Uttar Pradesh, India
[2] No India Engn Coll, Fac Pharm, Lucknow 227105, Uttar Pradesh, India
关键词
Compritol; Glyceryl behenate; Solid lipid nanoparticles; Aceclofenac; Taguchi experimental design; SLN;
D O I
10.1007/s11746-010-1618-6
中图分类号
O69 [应用化学];
学科分类号
070301 [无机化学];
摘要
The aim of this study was to explore the use of glyceryl behenate (GB) as a candidate lipid for the production of solid lipid nanoparticles (SLN) using the anti-inflammatory drug, aceclofenac, as an example. SLN were produced using the Gasco microemulsion method with three different lipids, namely GB, glyceryl palmitostearate (GP) and cetyl alcohol (CA). The prepared SLN were subjected to determination of entrapment, zeta potential, particle size, in vitro dissolution, entrapment efficiency and biodistribution. Stable SLN of GB having size 245 +/- 5 nm were prepared with a polydispersity index of 0.470. The size range was higher with other lipids i.e., CA and GP. It was found that as the drug lipid molar concentration was raised, particles with a smaller size were obtained irrespective of the nature of the lipid. The surfactant poloxamer 188 gave best results when used at a concentration of 2.5% w/v of dispersion. The study recommends GB as a suitable candidate for the production of SLN.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 12 条
[1]
4′-hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes [J].
Akimoto, H ;
Yamazaki, R ;
Hashimoto, S ;
Sato, T ;
Ito, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (03) :429-436
[2]
Gasco M.R., 1993, Patent, Patent No. [5,250,236, 5250236]
[3]
Jain N., 2001, ADV CONTROLLED NOVEL, P408
[4]
JOSE GR, 2003, Patent No. 6596308
[5]
Mader K., 2006, NANOPARTICULAES DRUG, P187, DOI [10.1142/9781860949074_0009, DOI 10.1142/9781860949074_0009]
[6]
Solid lipid nanoparticles as drug delivery systems [J].
Manjunath, K ;
Reddy, JS ;
Venkateswarlu, V .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2005, 27 (02) :127-144
[7]
Solid lipid nanoparticles -: Production, characterization and applications [J].
Mehnert, W ;
Mäder, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (2-3) :165-196
[8]
Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art [J].
Müller, RH ;
Mäder, K ;
Gohla, S .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :161-177
[9]
Pavia D L, 2007, CENGAGE, P26
[10]
Ranjit K.R., 2001, DESIGN EXPT USING TA